Role of pharmacogenetics in public health and clinical health care: A SWOT analysis

European Journal of Human Genetics

Volumn 24, Issue 12, 2016, Pages 1651-1657

  Kapoor, Ritika ^a   Tan Koi, Wei Chuen ^a,b   Teo, Yik Ying ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b HEALTH SCIENCES AUTHORITY   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACHIEVEMENT; ADVERSE DRUG REACTION; ANALYTIC METHOD; CLINICAL MEDICINE; DRUG COST; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOXICITY; DRUG UTILIZATION; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STRENGTHS, WEAKNESSES, OPPORTUNITIES AND THREATS ANALYSIS; DRUG THERAPY; ECONOMICS; GENETIC SCREENING; PERSONALIZED MEDICINE; STANDARDS; TRENDS;

DRUG THERAPY; GENETIC TESTING; PHARMACOGENETICS; PRECISION MEDICINE; PUBLIC HEALTH;

EID: 84984799164     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2016.114     Document Type: Review

References (55)

1. Lander ES, Linton LM, Birren B et al: Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Venter JC, Adams MD, Myers EW et al: The sequence of the human genome. Science 2001; 291: 1304-1351.
3. Collins FS, McKusick VA: Implications of the Human Genome Project for medical science. JAMA 2001; 285: 540-544.
4. Ojha RP, Thertulien R: Health care policy issues as a result of the genetic revolution: implications for public health. Am J Public Health 2005; 95: 385-388.
5. Klein TE, Altman RB, Eriksson N et al: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
6. Schwarz UI, Ritchie MD, Bradford Y et al: Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
7. Mallal S, Nolan D, Witt C et al: Association between presence of HLA-B∗5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
8. Mallal S, Phillips E, Carosi G et al: HLA-B∗5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
9. Chung WH, Hung SI, Hong HS et al: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
10. Hung SI, Chung WH, Liu ZS et al: Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11: 349-356.
11. Hung SI, Chung WH, Liou LB et al: HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-4139.
12. Somkrua R, Eickman EE, Saokaew S et al: Association of HLA-B∗5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011; 12: 118.
13. Ando Y, Saka H, Ando M et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
14. Innocenti F, Undevia SD, Iyer L et al: Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
15. Rouits E, Boisdron-Celle M, Dumont A et al: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151-5159.
16. Koren G, Cairns J, Chitayat D et al: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704.
17. Lehmann DS, Ribaudo HJ, Daar ES et al: Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 2015; 25: 51-59.
18. Ashley EA, Butte AJ, Wheeler MT et al: Clinical assessment incorporating a personal genome. Lancet 2010; 375: 1525-1535.
19. Rabbani B, Nakaoka H, Akhondzadeh S et al: Next generation sequencing: implications in personalized medicine and pharmacogenomics. Mol Biosyst 2016; 12: 1818-1830.
20. Welter D, MacArthur J, Morales J et al: The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2014; 42: D1001-D1006.
21. Whirl-Carrillo M, McDonagh EM, Hebert JM et al: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Therap 2012; 92: 414-417.
22. Chan SL, Suo C, Lee SC et al: Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J 2012; 12: 312-318.
23. Cooper GM, Johnson JA, Langaee TY et al: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027.
24. Marsh S, Hoskins JM: Irinotecan pharmacogenomics. Pharmacogenomics 2010; 11: 1003-1010.
25. Iyer L, Das S, Janisch L et al: UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
26. Hoskins JM, Goldberg RM, Qu P et al: UGT1A1∗28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290-1295.
27. Brown JT, Bishop JR: Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Pharmacogenomics 2015; 16: 1513-1520.
28. Michelson D, Read HA, Ruff DD et al: CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46: 242-251.
29. Sultana J, Cutroneo P, Trifiro G: Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 2013; 4: S73-S77.
30. Rauch A, Nolan D, Martin A et al: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99-102.
31. Whitney K: PREDICT helps pinpoint right statin for patient: Reporter: Vanderbilt University Medical Center: Nashville, TN, USA, 2012.
32. Moja L, Tagliabue L, Balduzzi S et al: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4: CD006243.
33. Dong D, Sung C, Finkelstein EA: Cost-effectiveness of HLA-B∗1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012; 79: 1259-1267.
34. Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N et al: Economic evaluation of HLA-B∗15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia 2013; 54: 1628-1638.
35. Tiamkao S, Jitpimolmard J, Sawanyawisuth K et al: Cost minimization of HLA-B∗1502 screening before prescribing carbamazepine in Thailand. Int J Clin Pharm 2013; 35: 608-612.
36. Kapoor R, Martinez-Vega R, Dong D et al: Reducing hypersensitivity reactions with HLA-B∗5701 genotyping before abacavir prescription: clinically useful but is it costeffective in Singapore? Pharmacogenet Genomics 2015; 25: 60-72.
37. Park WB, Choe PG, Song KH et al: Should HLA-B∗5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009; 48: 365-367.
38. Schackman BR, Scott CA, Walensky RP et al: The cost-effectiveness of HLA-B∗5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22: 2025-2033.
39. Nieves Calatrava D, Calle-Martin Ode L, Iribarren-Loyarte JA et al: Cost-effectiveness analysis of HLA-B∗5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm Infecc Microbiol Clin 2010; 28: 590-595.
40. Hughes DA, Vilar FJ, Ward CC et al: Cost-effectiveness analysis of HLA B∗5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14: 335-342.
41. Shotelersuk V, Limwongse C, Mahasirimongkol S: Genetics and genomics in Thailand: challenges and opportunities. Mol Genet Genomic Med 2014; 2: 210-216.
42. Shuldiner AR, O'Connell JR, Bliden KP et al: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
43. Pare G, Eikelboom JW, Sibbing D et al: Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2011; 4: 514-521, discussion 521.
44. Li Y, Tang HL, Hu YF et al: The gain-of-function variant allele CYP2C19∗17: a doubleedged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 2012; 10: 199-206.
45. Chan SL, Suo C, Chia KS et al: The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. Pharmacogenomics 2012; 13: 1247-1256.
46. Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 2007; 120: 1-10.
47. Ramsey LB, Bruun GH, Yang W et al: Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012; 22: 1-8.
48. Lesko LJ, Woodcock J: Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002; 2: 20-24.
49. Surendiran A, Pradhan SC, Adithan C: Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol 2008; 40: 137-143.
50. Relling MV, McDonagh EM, Chang T et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 2014; 96: 169-174.
51. Caudle KE, Klein TE, Hoffman JM et al: Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014; 15: 209-217.
52. Relling MV, Klein TE: CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464-467.
53. Swen JJ, Nijenhuis M, de Boer A et al: Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-673.
54. Kimmel SE, French B, Kasner SE et al: A pharmacogenetic versus a clinical algorithm for Warfarin Dosing. N Engl J Med 2013; 369: 2283-2293.
55. Baker WL, Chamberlin KW: New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? Clin Pharmacol Ther 2014; 96: 17-19.